Seema Gosavi
Research Subjects
Research Interests
Seema Gosavi has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Aditi Kulkarni
Department of Pharmacognosy, Smt. Kashibai Navale College of Pharmacy, Kondhwa (Bk), Affiliated to Savitribai Phule Pune University, Pune, Maharashtra, India
1 shared publication Aditi S Kulkarni
Department of Pharmacognosy, Smt. Kashibai Navale College of Pharmacy, Kondhwa, Pune, Maharashtra, India
1 shared publication- Girija Balasaheb Bhavar
Shri Vile Parle Kelavani Mandal’s Institute of Pharmacy, Dhule (M.S.), India
1 shared publication Jyoti B Tangde
Department of Pharmaceutical Chemistry , PDEA’s College of Pharmacy, Hadapsar, Pune, Maharashtra, India
1 shared publication- Kajal Shirapure
Department of Quality Assurance Techniques, Sanjivani College of Pharmaceutical Education and Research, Kopargaon, Affiliated to Savitribai Phule Pune University, Pune, Maharashtra, India
1 shared publication - Prasad Laxman Gorde
College of Pharmaceutical Sciences, Pravara Institute of Medical Sciences (Deemed to be University), Loni, Ahmednagar, Maharashtra, India
1 shared publication
Latest Publications
- Open Access
- 18 August 2026
- Published by Manuscript Technomedia LLP in International Journal of Pharmaceutical Investigation
- Vol. 16 (4) , 1451-1456
Simultaneous Estimation of Moxifloxacin and Tolfenamic Acid: Development and Validation of UV-visible, HPLC, and HPTLC Methods
Objectives: This research emphasizes validating the HPLC, HPTLC, and UV-visible techniques for the simultaneous quantitative measurement of Moxifloxacin (MOX) and Tolfenamic Acid (TA) in veterinary formulations. Materials and Methods: The UV spectrophotometric analysis was performed at 291 nm for moxifloxacin and 272 nm for tolfenamic acid. For HPLC, chromatographic separation was achieved using a gradient technique on a reverse-phase C18 ODS column (250×4.6 mm, 5 µm particle size) with a mobile phase comprising 2% orthophosphoric acid and an acetonitrile with ratio of 80:20, with a 1 mL/min flow rate. Detection was accomplished at 254 nm. For HPTLC, separation was performed on pre-coated silica gel 60 F254 plates using a mobile phase of acetonitrile: water: formic acid: methanol:30% ammonia (8:1:1:1:2 v/v). Densitometric assessment for separate zones was performed at 230 nm. Results: The HPLC analysis of the current method exhibits the linearity range from 2 to 12 µg/mL for moxifloxacin and 1 to 6 µg/mL for tolfenamic acid in HPLC, 8 to 20 µg/spot for moxifloxacin and 4 to 9 µg/spot for tolfenamic acid in HPTLC, and 6 to 42 µg/mL for MOX and 3 to 21 µg/mL for TA in UV spectrophotometry. The methods were found to be accurate; recovery was achieved from 98 to 102%. The Relative Standard Deviation (RSD) for precision was found to be less than 2%. Conclusion: The proposed methods were successfully applied to the determination of MOX and TA in both bulk and veterinary tablet formulations. The methods were validated in accordance with ICH Q2-(R1) guidelines.
- 18 August 2026
- Published by Manuscript Technomedia LLP in International Journal of Pharmaceutical Investigation
- Vol. 16 (4) , 1451-1456
Open AccessSimultaneous Estimation of Moxifloxacin and Tolfenamic Acid: Development and Validation of UV-visible, HPLC, and HPTLC Methods
Objectives: This research emphasizes validating the HPLC, HPTLC, and UV-visible techniques for the simultaneous quantitative measurement of Moxifloxacin (MOX) and Tolfenamic Acid (TA) in veterinary formulations. Materials and Methods: The UV spectrophotometric analysis was performed at 291 nm for moxifloxacin and 272 nm for tolfenamic acid. For HPLC, chromatographic separation was achieved using a gradient technique on a reverse-phase C18 ODS column (250×4.6 mm, 5 µm particle size) with a mobile phase comprising 2% orthophosphoric acid and an acetonitrile with ratio of 80:20, with a 1 mL/min flow rate. Detection was accomplished at 254 nm. For HPTLC, separation was performed on pre-coated silica gel 60 F254 plates using a mobile phase of acetonitrile: water: formic acid: methanol:30% ammonia (8:1:1:1:2 v/v). Densitometric assessment for separate zones was performed at 230 nm. Results: The HPLC analysis of the current method exhibits the linearity range from 2 to 12 µg/mL for moxifloxacin and 1 to 6 µg/mL for tolfenamic acid in HPLC, 8 to 20 µg/spot for moxifloxacin and 4 to 9 µg/spot for tolfenamic acid in HPTLC, and 6 to 42 µg/mL for MOX and 3 to 21 µg/mL for TA in UV spectrophotometry. The methods were found to be accurate; recovery was achieved from 98 to 102%. The Relative Standard Deviation (RSD) for precision was found to be less than 2%. Conclusion: The proposed methods were successfully applied to the determination of MOX and TA in both bulk and veterinary tablet formulations. The methods were validated in accordance with ICH Q2-(R1) guidelines.
- Open Access
- 30 August 2023
- Published by International Academic Publishing House in INTERNATIONAL JOURNAL OF EXPERIMENTAL RESEARCH AND REVIEW
- Vol. 32, 387-397
Comparative analysis of analytical method development and its validation for the simultaneous estimation of Bilastine and Montelukast Sodium in bulk and its tablet formulation by planar chromatography
The development and validation of analytical methods are crucial in guaranteeing the precision, dependability, and excellence of pharmaceutical analysis. This research investigates the field of pharmaceutical chemistry by doing a comparative examination of analytical techniques for the simultaneous determination of Bilastine and Montelukast Sodium in both bulk and tablet forms. The selected method for this analysis is planar chromatography. The simplicity, specificity, precision, and accuracy of a high-performance liquid chromatography (HPTLC) approach were investigated for their use in the simultaneous estimation of the antihistaminic combination medication Bilastine and Montelukast Sodium in bulk and its pharmaceutical dose for the treatment of allergic rhinitis. Densitometric readings were taken at 254 nm after separating substances using ethyl acetate, toluene, methanol, and ammonia (7:0.5:1.5:0.5v/v/v/v) as mobile phase and precoated aluminium silica gel plates (60F254) as stationary phase. Bilastine and montelukast Sodium have Rf values 0.2 (Bilastine) & 0.4 (Montelukast Sodium), which is considered an acceptable resolution. The International Conference on Harmonization's (ICH) requirements validated the processes for accuracy, linearity, precision, robustness, and system adaptability. Bilastine and Montelukast Sodium concentrations were determined without any disruption from the excipients. Both Bilastine and Montelukast Sodium were effectively quantified using the suggested method, which bodes well for its utility in enhancing quality assurance.
- 30 August 2023
- Published by International Academic Publishing House in INTERNATIONAL JOURNAL OF EXPERIMENTAL RESEARCH AND REVIEW
- Vol. 32, 387-397
Open AccessComparative analysis of analytical method development and its validation for the simultaneous estimation of Bilastine and Montelukast Sodium in bulk and its tablet formulation by planar chromatography
The development and validation of analytical methods are crucial in guaranteeing the precision, dependability, and excellence of pharmaceutical analysis. This research investigates the field of pharmaceutical chemistry by doing a comparative examination of analytical techniques for the simultaneous determination of Bilastine and Montelukast Sodium in both bulk and tablet forms. The selected method for this analysis is planar chromatography. The simplicity, specificity, precision, and accuracy of a high-performance liquid chromatography (HPTLC) approach were investigated for their use in the simultaneous estimation of the antihistaminic combination medication Bilastine and Montelukast Sodium in bulk and its pharmaceutical dose for the treatment of allergic rhinitis. Densitometric readings were taken at 254 nm after separating substances using ethyl acetate, toluene, methanol, and ammonia (7:0.5:1.5:0.5v/v/v/v) as mobile phase and precoated aluminium silica gel plates (60F254) as stationary phase. Bilastine and montelukast Sodium have Rf values 0.2 (Bilastine) & 0.4 (Montelukast Sodium), which is considered an acceptable resolution. The International Conference on Harmonization's (ICH) requirements validated the processes for accuracy, linearity, precision, robustness, and system adaptability. Bilastine and Montelukast Sodium concentrations were determined without any disruption from the excipients. Both Bilastine and Montelukast Sodium were effectively quantified using the suggested method, which bodes well for its utility in enhancing quality assurance.